[Pomalidomide for multiple myeloma]
- PMID: 28583668
- DOI: 10.1016/j.bulcan.2017.04.005
[Pomalidomide for multiple myeloma]
Abstract
Pomalidomide is a second-generation immunomodulatory drug (IMID). Its efficiency overtakes its predecessors' (thalidomide, lenalidomide), with less toxicity. It is indicated in the treatment of refractory or relapsed multiple myeloma, associated to dexamethasone. It is available in France since 2013, following the results of different studies.
Keywords: IMID; Multiple myeloma; Myélome multiple; Pomalidomide; Rechute ou réfractaire; Relapsed or refractory.
Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
Similar articles
-
Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Expert Rev Anticancer Ther. 2014 May;14(5):499-510. doi: 10.1586/14737140.2014.906904. Epub 2014 Apr 17. Expert Rev Anticancer Ther. 2014. PMID: 24738833 Review.
-
Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.Crit Rev Oncol Hematol. 2013 Oct;88 Suppl 1:S36-44. doi: 10.1016/j.critrevonc.2013.02.001. Epub 2013 Jun 17. Crit Rev Oncol Hematol. 2013. PMID: 23786844 Review.
-
Pomalidomide for the management of refractory multiple myeloma.Am J Health Syst Pharm. 2014 Sep 1;71(17):1443-8. doi: 10.2146/ajhp130752. Am J Health Syst Pharm. 2014. PMID: 25147167 Review.
-
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.Curr Cancer Drug Targets. 2017;17(9):846-857. doi: 10.2174/1568009617666170214104426. Curr Cancer Drug Targets. 2017. PMID: 28201976 Review.
-
Pomalidomide for multiple myeloma.Expert Rev Hematol. 2014 Dec;7(6):719-31. doi: 10.1586/17474086.2014.966074. Epub 2014 Sep 30. Expert Rev Hematol. 2014. PMID: 25265911 Review.
Cited by
-
Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study.J Cancer Res Clin Oncol. 2022 Apr;148(4):975-984. doi: 10.1007/s00432-021-03693-5. Epub 2021 Jun 18. J Cancer Res Clin Oncol. 2022. PMID: 34143239 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical